Member of the Board of Directors since April 2022
Education: PhD and MSc Pharm
Background: Worked all her career in drug development. First in Nycomed Pharma for 18 years in various leadership positions in Project Management, Clinical Development, Regulatory Affairs and as overall responsible for Drug Development being part of Nycomed top-management. In 2008 Alejandra acquired KLIFO A/S to build an international drug development consultancy supporting biotech and pharma companies to progress and increase value of their product development projects. Alejandra Mørk has since 2011 been member of the Board of Danish Biotech.
Other ongoing assignments: Board member in Danish Biotech, Epoqe Pharma ApS and member of the Danish Academy of Technical Sciences.
Independence: Independent in relation to both the Company and executive management.
Scandion Oncology shares and warrants:
64.271 warrants.